Hyderabad-based GVK Biosciences (GVK BIO), contract research organization, has commissioned a new clinical pharmacology unit (CPU) in Ahmedabad, India. The Ahmedabad CPU adds 110 beds to GVK BIO’s existing capacity of 144 beds. The new CPU will conduct a variety of studies in healthy volunteers.
The company is a leading service provider of bioequivalence studies to generic pharma companies globally. The comapny's CPU unit in Hyderabad is operational since 2004. "The opening of the new GVK BIO Clinical Pharmacology unit reflects our commitment to offer faster recruitment solutions to our customers. The facility has been audited by the DCGI and we have initiated our first study at the Ahmedabad facility”, said Manni Kantipudi, President, GVK Biosciences.
GVK BIO provides a broad spectrum of services across the R&D value chain. The company's portfolio includes more than 100 customers includes Big Pharma, Agri & Life–sciences companies, leading biotechs, generic pharma and academic institutions. The company is spread across five locations in India.
